Celcuity Inc. (CELC) is a clinical-to-commercial stage biotechnology company in Minneapolis developing gedatolisib, a dual PI3K/mTOR inhibitor for advanced breast cancer. Reviewing current, individually attributed targets — including H.C. Wainwright ($155, October 2026), J.P. Morgan ($157, September 2026), Leerink Partners ($147, October 2026), Needham ($134, September 2026), Guggenheim ($175, August 2026), Craig-Hallum ($173, August 2026), Citizens JMP ($177, August 2026), Wells Fargo ($166, August 2026), LifeSci Capital ($165, August 2026), and Stifel ($150, August 2026) — produces a mean of roughly $160.
The spread is wide, from about $134 to $177, reflecting genuine disagreement over how quickly gedatolisib sales will ramp. Most covering analysts rate the stock Buy, yielding a "Strong Buy" to "Moderate Buy" stance overall, but the range is unusually broad because valuation depends on early launch execution. Notably, Zacks Research cut CELC to "strong sell" in mid-October 2026, while Needham and Stifel trimmed targets — underscoring that not every sell-side view is bullish.
As of mid-October 2026, CELC trades near $60, down sharply from its 52-week high of $151.02 set in May 2026. That means the $160 target sits roughly 167% above the latest price — a very large required move that would effectively require the stock to more than double. Reaching it likely depends on REVTORPYK building real prescription momentum and on the company widening its label into the PIK3CA-mutant population, not merely on retaining current expectations.
The core bull case is now commercial rather than purely clinical. The FDA approved REVTORPYK in July 2026 for HR-positive, HER2-negative advanced breast cancer, and the drug became commercially available on September 30, 2026. Unlike selective PI3K inhibitors from Novartis (NVS) and Pfizer (PFE)-partnered rivals, gedatolisib works in the PIK3CA wild-type majority. Management has cited a multi-billion-dollar addressable market, and Celcuity filed a supplemental application in August 2026 to expand into PIK3CA-mutant patients. Roughly $754 million in cash provides funding runway.
The stock has fallen roughly 60% from its May 2026 peak even after approval and launch. Investors have focused on tolerability (high rates of mouth inflammation in studies), a delayed commercial launch, and a second-quarter net loss of about $78.9 million, with EPS (earnings per share) missing consensus. The company carries $575 million in convertible notes due 2032, creating future dilution risk, and short interest is high at over 20% of shares outstanding. With essentially no revenue history, any slow launch or disappointing first sales figures could compress valuation further. Competition, cash burn, and execution risk in a first-ever commercial launch all remain material.
The chart has deteriorated markedly. CELC trades below its 50-day moving average near $84 and its 200-day moving average near $100–104, with the RSI (relative strength index) in oversold territory near 30. The prior $70–71 shelf has broken, and the $85–88 zone — former support — now acts as resistance. The 52-week low near $46.51 marks the next major downside reference, while any durable recovery would first need to reclaim the mid-$80s before the $100+ zone becomes relevant again.
Analyst price targets generally reflect a roughly 12-month research horizon. The key near-term catalyst is the next earnings report, estimated for November 11, 2026, which will offer the first meaningful read on REVTORPYK prescriptions and revenue. Investors should also track the supplemental label-expansion filing for PIK3CA-mutant patients, updates on the VIKTORIA-2 and prostate-cancer trials, quarterly cash burn, and any further analyst target revisions, which have recently been trending lower.
Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use the tool to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review allows. For a volatile, catalyst-driven name like CELC, supplementing fundamental research with real-time signal monitoring can help identify changes in momentum as they develop.
Can CELC reach $160? The target is a legitimate, analyst-derived average of current buy-rated price objectives, and it sits far above the recent price — meaning the stock would need to more than double. The bull case rests on successful commercialization of REVTORPYK and label expansion, while the bear case points to a sharp post-approval decline, widening losses, dilution, and elevated short interest. Analysts disagree widely on the path, with targets spanning roughly $134 to $177. Reaching $160 is not a forecast but a scenario contingent on launch execution and clinical-regulatory progress that remains unproven.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CELC has been closely correlated with IMA. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if CELC jumps, then IMA could also see price increases.
| Ticker / NAME | Correlation To CELC | 1D Price Change % | ||
|---|---|---|---|---|
| CELC | 100% | +3.95% | ||
| IMA - CELC | 76% Closely correlated | -1.71% | ||
| SLXN - CELC | 50% Loosely correlated | +2.90% | ||
| IMTX - CELC | 44% Loosely correlated | +0.21% | ||
| ABVX - CELC | 43% Loosely correlated | +4.48% | ||
| DNTH - CELC | 42% Loosely correlated | +0.55% | ||
More | ||||